Fatal injection of ranitidine: A case report

Antonio Oliva, Sara Partemi, Vincenzo Arena, Fabio De Giorgio, Catia Colecchi, Nadia Fucci, Vincenzo Lorenzo Pascali

Research output: Contribution to journalArticle


Introduction: Ranitidine hydrochloride (Zantac®), a histamine-2-receptor antagonist, is a widely used medication with an excellent safety record. Anaphylactic reaction to ranitidine is an extremely rare event and a related death has never been described in the literature. Case presentation: We present the clinical history, histological and toxicological data of a 51-year-old man with negative anamnesis for allergic events, who died suddenly after the intravenous administration of one phial of Zantac® 50 mg prescribed as a routine post-surgical prophylaxis for stress ulcer. Conclusion: Although the incidence of anaphylactic reactions related to ranitidine is low, caution needs to be exercised on administration of this drug. In addition, further study is needed to define strategies for the prevention of adverse drug reactions in hospitalized patients. © 2008 Oliva et al; licensee BioMed Central Ltd.
Original languageEnglish
Pages (from-to)232-232
Number of pages1
JournalJournal of Medical Case Reports
Publication statusPublished - 2008


  • alfuzosin
  • anamnesis
  • anaphylactic shock
  • article
  • autopsy
  • blood toxicity
  • brain edema
  • case report
  • cefodizime
  • consciousness disorder
  • drug fatality
  • drug hypersensitivity
  • dyspnea
  • histopathology
  • hospital admission
  • human
  • hypotension
  • immediate type hypersensitivity
  • lung congestion
  • lung edema
  • male
  • petechia
  • prescription
  • priority journal
  • prostate hypertrophy
  • ranitidine, adult
  • stress ulcer
  • transurethral resection
  • wheezing


Dive into the research topics of 'Fatal injection of ranitidine: A case report'. Together they form a unique fingerprint.

Cite this